Abstract P1081: Urine Metabolomic Profiles Associated with Incident Heart Failure in Older Adults
Abstract
Introduction: Metabolomic biomarkers have enhanced heart failure (HF) prediction in addition to clinical risk factors. However, urine metabolites related to incident HF have not been studied. Hypothesis: Novel urine metabolites, as well as uremic toxins, are associated with an increased risk of HF. Methods: Metabolomic profiling was performed in the Atherosclerosis Risk in Communities (ARIC) study at visit 5 using urine samples. Urine metabolite levels were probabilistic quotient normalized prior to the analyses, and 914 known urine metabolites were evaluated with incident HF using Cox proportional hazard regression. Replication analyses were performed on 3,431 participants, including 172 HF cases (mean age=58) from the German Chronic Kidney Disease (GCKD) study (100% Whites). Results: During an average of 7 years of follow-up, 226 incident HF events occurred among 1,242 ARIC participants (54.3% Whites, mean age= 76). After adjusting for clinical risk factors and eGFR, ten urine metabolites were associated with incident HF (FDR p-value <0.05). Guanosine-3',5'-cyclic monophosphate (cGMP), a biologic marker reflecting renal activities of natriuretic peptides, was associated with an increased risk of HF (HR=1.40, 95% CI= 1.21-1.63). Sucrose, a disaccharide composed of glucose and fructose, was also associated with an increased effect on HF (HR=1.30, 95% CI= 1.12-1.50), and the effect persisted with further adjustment of fasting glucose levels. The associations of urine cGMP and sucrose with HF were replicated in GCKD (HR cGMP =1.40, 95% CI= 1.24-1.56; HR sucrose = 1.19, 95% CI= 1.03-1.35, Figure). Additional analyses revealed that cGMP was more strongly associated with HF with reduced (HFrEF) than with preserved ejection fraction (HFpEF), while sucrose was more strongly associated with HFpEF than HFrEF. Conclusions: Urinary metabolites associated with incident HF and its subtypes were identified, providing complementary insights into the molecular mechanism of the development of HF.
Article Details
Authors (16)
Shinhye Chung
University of Texas Health Science Center at Houston, School of Public Health, Houston, Texas, United States
Elena Butz
University of Freiburg, Freiburg, Germany
Ngoc Quynh Nguyen
UTHealth School of Public Health, Houston, Texas, United States
Guning Liu
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Eun Hye Moon
UTHealth at Houston, Houston, Texas, United States
Ron Hoogeveen
BAYLOR COLLEGE MEDICINE, Houston, Texas, United States
Christie Ballantyne
BAYLOR COLLEGE MEDICINE, Houston, Texas, United States
Amil Shah
University of Texas Southwestern Medical Center, Dallas (A.S.).
Paul Kimmel
National Institutes of Health, Bethesda, Maryland, United States
Vasan Ramachandran
The University of Texas San Antonio School of Public Health, San Antonio, Texas, United States
Pascal Schlosser
Anna Koettgen
Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States
Morgan Grams
NYU Grossman School of Medicine, New York, New York, United States
Josef Coresh
Peggy Sekula
University of Freiburg, Friburg, Germany
Bing Yu
College of Chemistry and Materials Science, Guangdong Provincial Key Laboratory of Supramolecular Coordination Chemistry